487

10. Morran C, Smith DC, Anderson DA, McArdle CS. Incidence of nausea and vomiting with cytotoxic chemotherapy in a prospective randomised trial of antiemetics. Br Med J 1979; i: 1323-25. 11. Schmoll HJ. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimens. Eur J Cancer Clin Oncol 1989; 25 (suppl): 535-39. 12. Aapro M, Plezzia PM, Alberts D S, et al. Double-blind crossover study of the anti-emetic efficacy of high dose dexamethasone versus high dose metaclopramide. J Clin Oncol 1983; 2: 466-71. 13. Markman M, Sheilder V, Ettinger DS, et al. Anti-emetic study of dexamethasone. Randomised double-blind, crossover study with high dose metoclopramide in patients receiving cancer chemotherapy. N Engl J Med 1984; 331: 549-22. 14. Ibrahim EM, Al-Idrissi HY, Ibrahim A, et al. Anti-emetic efficacy of high dose dexamethasone: randomised double-blind crossover study with high dose metoclopramide in patients receiving cancer chemotherapy. Eur J Cancer Clin Oncol 1986; 22: 283-88. 15. Rich WM, Abdulhayoglu G, Disaia PJ. Methylprednisolone as an antiemetic during cancer chemotherapy: a pilot study. Gynaecol Oncol 1980; 9: 193-98. 16. Kenward MG, Fleming TR. A log-linear model for binary crossover data. Appl Statistics 1987; 36: 192-204.

17. Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972; 28: 577-84. 18. Drapkin RL, Sokol GH, Paladino WJ, et al. The antiemetic effect and dose response of dexamethasone in patients receiving cisplatinum. Proc Am Soc Clin Oncol 1982; 1: C236. 19. Kris MG, Gralla RJ, Tyson LB, et al. Incidence, course and severity of delayed nausea and vomiting following the administration of high dose cisplatin. J Clin Oncol 1985; 3: 1379-84. 20. Lindley CM, Bernard S, Fields SM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 1989; 7: 1142-49. 21. Hawthorn J, Cunningham D. Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide-induced vomiting in the ferret. Br J Cancer 1990; 61: 56-60. 22. Olver IN, Simon RH, Aisner J. Anti-emetic studies: a methodological discussion. Cancer Treat Rep 1976; 70: 555-63. 23. Eisman JA. Long term corticosteroid therapy-managing side-effects. Concurrent Therapy 1986; 27: 42-46. 24. Cunningham D, Turner A, Hawthorn J, Rosin RD. Ondansetron with

and without dexamethasone Lancet 1989; i: 1323.

to treat

chemotherapy-induced

emesis.

Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy

Ondansetron,

serotonin antagonist, is effective in controlling the emesis associated with cancer chemotherapy; however, emesis in patients receiving high-dose cisplatin is poorly controlled by ondansetron alone. Dexamethasone is an effective antiemetic with no known interaction with serotonin receptors and was thus chosen for study in combination with ondansetron. 31 patients (30 male, 1 female; median age 28·5 a

range 18-49) receiving a 4-day course of a chemotherapy regimen containing cisplatin (100120 mg/m2) for metastatic germ-cell tumours were

years,

entered in a randomised, double-blind, cross-over trial comparing oral ondansetron plus placebo with oral ondansetron plus dexamethasone as antiemetic prophylaxis. Ondansetron (8 mg every 8 h) was given to all patients for 8 days from the start of chemotherapy. Patients were given 8 mg of dexamethasone or placebo every 8 h starting 2 h before cisplatin (on day 4) and continuing for six doses (ie, for 2 days only). A second course of chemotherapy began 14 days after the start of the first, during which patients crossed over to the alternative antiemetic regimen. Results were available from 27 patients. In the 24-48 h after cisplatin 78% of patients taking ondansetron plus dexamethasone reported complete or major control of emesis compared with 30% of those taking ondansetron plus placebo (p=0·001). Cross-over analysis showed a significant advantage for ondansetron plus dexamethasone in the control of nausea (p=0·013) and emesis (p

Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.

Ondansetron, a serotonin antagonist, is effective in controlling the emesis associated with cancer chemotherapy; however, emesis in patients receiving...
582KB Sizes 0 Downloads 0 Views